Profil
Jeffrey R.
Latts is an Independent Director at Allos Therapeutics, Inc. since 2007.
Previously, he served as the Chief Medical Officer at Berlex, Inc. from 1990 to 2001.
He then worked as the Executive Vice President at Exelixis, Inc. from 2001 to 2007.
Additionally, he has held positions as the Chief Medical Advisor at Virobay, Inc. and as the Vice President-Clinical Research at Wyeth-Ayerst Research.
Dr. Latts completed his undergraduate and doctorate degrees at the University of Minnesota.
Postes actifs de Jeffrey R. Latts
| Sociétés | Poste | Début |
|---|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Directeur/Membre du Conseil | 25/04/2007 |
Anciens postes connus de Jeffrey R. Latts
| Sociétés | Poste | Fin |
|---|---|---|
| EXELIXIS, INC. | Corporate Officer/Principal | 12/01/2007 |
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Manufactured pharmaceutical products | Directeur Technique/Scientifique/R&D | 01/01/2001 |
Virobay, Inc.
Virobay, Inc. Pharmaceuticals: MajorHealth Technology Develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases | Corporate Officer/Principal | - |
Wyeth-Ayerst Research | Directeur Technique/Scientifique/R&D | - |
Formation de Jeffrey R. Latts
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Berlex, Inc.
Berlex, Inc. Pharmaceuticals: MajorHealth Technology Manufactured pharmaceutical products | Health Technology |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Health Technology |
Exelixis, Inc.
Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Virobay, Inc.
Virobay, Inc. Pharmaceuticals: MajorHealth Technology Develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases | Health Technology |
University of Minnesota
University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wyeth-Ayerst Research |
















